Edition:
India

People: AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

16.80USD
14 Dec 2018
Change (% chg)

$-0.19 (-1.12%)
Prev Close
$16.99
Open
$16.81
Day's High
$17.22
Day's Low
$16.40
Volume
228,090
Avg. Vol
222,456
52-wk High
$26.08
52-wk Low
$11.95

Santini, Gino 

Mr. Gino Santini is Independent Chairman of the Board of the Company. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004 and President of the women's health franchise from 1997 to 1999. Mr. Santini has served on the Board of Directors of Intarcia Therapeutics, Inc., a biopharmaceutical company, since July 2013. He has also served on the Board of Directors of Collegium Pharmaceuticals, Inc., a public pharmaceutical company, since July 2012, where he is the chair of the Nominating & Corporate Governance Committee and a member of the Compensation Committee. Mr. Santini has also served on the Board of Directors of Allena Pharmaceuticals, Inc., a specialty pharmaceutical company, since 2012 and Artax Biopharma Inc., a biopharmaceutical company, since April 2014. Since December 2015, Mr. Santini has served on the Board of Directors of Intercept Pharmaceuticals, Inc. a public biopharmaceutical company, where he is also the chair of the Compensation Committee and a member of the Audit Committee. Mr. Santini also serves on the Board of Directors, as well as the Chair of the Transactions Committee and a member of the Nominating and Corporate Governance Committee of the Board of Directors, of Horizon Pharma, Plc., a public biopharmaceutical company, where he has been a director since 2012. Mr. Santini was a member of the Board of Directors of Vitae Pharmaceuticals, Inc., a public pharmaceutical company, from September 2014 to November 2016 when it was acquired by Allergan plc in October 2016. He holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 87,491
Long-Term Incentive Plans, USD --
All Other, USD 195,496
Fiscal Year Total, USD 282,987

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gino Santini

282,987

William Heiden

4,349,050

Edward Myles

1,279,600

Elizabeth Bolgiano

--

Joseph Vittiglio

1,203,710

Julie Krop

1,270,570
As Of  31 Dec 2017